Phase II trial of tasquinimod shows overall survival benefit


A paper in Clinical Cancer Research has reported an overall survival (OS) benefit of the investigational drug tasquinimod compared to a placebo in men with castration-resistant prostate cancer after treatment with docetaxel-based chemotherapy.

These data come from the long-term follow-up of the randomized Phase II trial of tasquinimod, and we shall have to wait for the results of the ongoing Phase III trial to confirm these results, but, according to this paper by Armstrong et al.:

  • Patients taking tasquinimod had a median OS of 33.4 months compared to 30.4 months for men treated with a placebo.
  • Patients whose cancer had already metastasized to their bones survived an average of 34.2 months, compared to 27.1 months for men treated with a placebo.

Additional information about this study can be found in a media release from the Duke University Health System; in an article on the OncLive web site; and in the actual paper by Armstrong et al.

It is worth remembering that few of the patients originally enrolled in this Phase II trial would have received either abiraterone acetate or enzalutamide prior to their initial treatment with either tasquinimod or the placebo, and that some of these patients may well have received abiraterone acetate or enzalutamide (or both) after their treatment with tasquinimod. It may be difficult, as a consequence, to know how much of the survival benefit shown in this trial is a direct consequence of treatment with tasquinimod itself. This is one of the reasons that the outcome of the later Phase III trial will be very important.

Median OS was 33.4 months in the tasquinimod group versus 30.4 months for those taking placebo, investigators Armstrong et al reported. Results were best for the subgroup of 136 men in the study who had bone metastases; they experienced a 34.2 month OS as compared to 27.1 months for those who took placebo, the authors wrote.PFS lasted an average 7.6 months for men taking tasquinimod, as compared with 3.3 months for those on placebo; among men with bone metastases, those numbers rose to 8.4 months in the experimental group versus 3.4 months in the control group, Duke reported in an announcement about the findings.2 – See more at: http://www.onclive.com/publications/urologists-in-cancer-care/2013/December-2013/Tasquinimod-Improves-OS-PFS-in-CRPC-Data-Show?utm_source=Informz&utm_medium=OncLive&utm_campaign=Prostate%20eNews%20Zytiga%2001-22-14#sthash.impQwIoj.dpuf

Median OS was 33.4 months in the tasquinimod group versus 30.4 months for those taking placebo, investigators Armstrong et al reported. Results were best for the subgroup of 136 men in the study who had bone metastases; they experienced a 34.2 month OS as compared to 27.1 months for those who took placebo, the authors wrote.PFS lasted an average 7.6 months for men taking tasquinimod, as compared with 3.3 months for those on placebo; among men with bone metastases, those numbers rose to 8.4 months in the experimental group versus 3.4 months in the control group, Duke reported in an announcement about the findings.2 – See more at: http://www.onclive.com/publications/urologists-in-cancer-care/2013/December-2013/Tasquinimod-Improves-OS-PFS-in-CRPC-Data-Show?utm_source=Informz&utm_medium=OncLive&utm_campaign=Prostate%20eNews%20Zytiga%2001-22-14#sthash.impQwIoj.dpuf

Median OS was 33.4 months in the tasquinimod group versus 30.4 months for those taking placebo, investigators Armstrong et al reported. Results were best for the subgroup of 136 men in the study who had bone metastases; they experienced a 34.2 month OS as compared to 27.1 months for those who took placebo, the authors wrote.PFS lasted an average 7.6 months for men taking tasquinimod, as compared with 3.3 months for those on placebo; among men with bone metastases, those numbers rose to 8.4 months in the experimental group versus 3.4 months in the control group, Duke reported in an announcement about the findings.2 – See more at: http://www.onclive.com/publications/urologists-in-cancer-care/2013/December-2013/Tasquinimod-Improves-OS-PFS-in-CRPC-Data-Show?utm_source=Informz&utm_medium=OncLive&utm_campaign=Prostate%20eNews%20Zytiga%2001-22-14#sthash.impQwIoj.dpuf

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: